MPH Health Care AG: insider trades · Germany · BaFin

About MPH Health Care AG

MPH Health Care AG is a German investment holding company listed on Xetra/Frankfurt (DAX/MDAX/SDAX) under ticker 93M1.DE, with headquarters in Berlin, Germany. Founded in 2008 and listed since 2009, MPH is not a traditional operating healthcare provider. Instead, it is a portfolio company focused on long-term value creation through the acquisition, development, and disposal of companies and equity stakes. Its strategic focus is concentrated on growth segments of the healthcare market, especially medical aesthetics, chronic diseases, and healthcare digitalisation, while also remaining open to other profitable sectors, including real estate. MPH’s corporate message emphasizes a cost-efficient “best value” approach: for its portfolio businesses, the aim is usually price leadership combined with high quality in services, products, and medical care. In practice, the business model is built around active ownership, portfolio development, and the management of listed stakes rather than direct healthcare operations. The company identifies M1 Kliniken AG and CR Energy AG as its direct listed holdings, with an indirect interest in HAEMATO AG. M1 Kliniken is the flagship investment and gives MPH exposure to the medical aesthetics market, a segment the group highlights as one of its core growth engines. From a competitive standpoint, MPH sits in a distinct niche among German small-cap investment companies. Its equity story is driven less by consolidated operating revenue and more by the valuation of its quoted holdings, net asset value, and balance-sheet strength. As a result, the stock tends to be highly sensitive to market movements in portfolio companies and to fair-value revaluations under IFRS. MPH reports under IFRS and publishes regular interim and annual updates for investors. Recent developments have been material. In May 2025, MPH reported its 2024 annual results, showing net profit of EUR 32.0 million, EBIT of EUR 33.0 million, equity of EUR 277.9 million, and NAV per share of EUR 64.90, alongside a proposed dividend of EUR 1.20 per share. During 2025, however, the group was negatively affected by the sharp decline in the share price of CR Energy AG, which later entered preliminary insolvency proceedings, leading to significant fair-value losses and weaker interim results. At the same time, M1 Kliniken continued to deliver solid operating growth, helping to preserve the quality of the overall portfolio. For investors, MPH remains a balance-sheet-led, event-driven holding story rather than a conventional healthcare operating company.